Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T02001 | ||||
Target Name | Phosphodiesterase 4D (PDE4D) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 19100 nM | [4] | |
1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione | Drug Info | Ki = 10600 nM | [4] | ||
CC-1088 | Drug Info | IC50 = 1100 nM | [13] | ||
CDP840 | Drug Info | IC50 = 14 nM | [7] | ||
CI-1018 | Drug Info | IC50 = 1100 nM | [5] | ||
DENBUFYLLINE | Drug Info | IC50 = 170 nM | [1] | ||
isobutylmethylxanthine | Drug Info | IC50 = 6900 nM | [12] | ||
L-454560 | Drug Info | IC50 = 1.2 nM | [11] | ||
L-869298 | Drug Info | IC50 = 0.4 nM | [9] | ||
Ro 20-1724 | Drug Info | IC50 = 9100 nM | [12] | ||
ROLIPRAM | Drug Info | IC50 = 550 nM | [10] | ||
SCH-351591 | Drug Info | IC50 = 60 nM | [3] | ||
SCH-351591 | Drug Info | IC50 = 51 nM | [2] | ||
UCB-101333-3 | Drug Info | IC50 = 630 nM | [8] | ||
ZAPRINAST | Drug Info | Ki = 8760 nM | [6] | ||
ZARDAVERINE | Drug Info | IC50 = 390 nM | [10] | ||
References | |||||
REF 1 | Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. | ||||
REF 2 | 8-Methoxyquinolines as PDE4 inhibitors. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1617-9. | ||||
REF 3 | Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. | ||||
REF 4 | Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44. | ||||
REF 5 | New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6. | ||||
REF 6 | 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. J Med Chem. 2005 Feb 24;48(4):1237-43. | ||||
REF 7 | Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. | ||||
REF 8 | First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. | ||||
REF 9 | Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73. | ||||
REF 10 | In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. | ||||
REF 11 | The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5. | ||||
REF 12 | A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. | ||||
REF 13 | Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.